• Medzown Tackling Flaws in Clinical Trial Enrollment Ecosystem

    Clinical Research News | A startup precision medicine management company is “cracking the code” on how to make cutting-edge treatments more accessible to patients and at the same time financially sustainable for all stakeholders. The approach of 3-year-old Medzown collapses the boundaries between clinical care and clinical trials to create a unified care pathway, according to founder and CEO Jennifer Levin Carter, M.D.

    Oct 15, 2026

  • A Vision for Connecting Better Care with Better Clinical Trial Design

    Clinical Research News | The latest episode of the Scope of Things podcast shares a conversation between Michelle Snyder of McKesson and Synapticure CEO Sandra Abravaya as they follow Abravaya’s path from public service to healthcare entrepreneurship, grounded in an ALS caregiver’s view of what happens when guidance is unavailable at the moment it matters most.

    Oct 13, 2026

  • Lab-Grown Brain Models Could Bring ‘Clinical Trials in a Vial,’ Harvard Researcher Says

    Clinical Research News | Brain organoids, three-dimensional tissues grown from stem cells, are edging closer to the clinic, with researchers envisioning a future in which a patient's response to a drug can be tested in a lab dish before they ever enroll in a study.

    Oct 8, 2026

  • The Evolution of RBQM: From Regulatory Compliance to Proven ROI and Data Quality

    Clinical Research News | Today, RBQM offers not just regulatory compliance but the ability to add measurable value to drug development and sponsor organizations. However, many organizations are still operating with fragmented tools, static risk registers and reactive monitoring models. To unlock the true power of RBQM, the industry needs to embrace its potential as a live, operational oversight model.

    Oct 6, 2026

  • Follow the Money: Phase 3 Thyroid Eye Disease, Pivotal Dravet Syndrome Gene Therapy, Pediatric Brain Cancer CAR T

    Clinical Research News | Funding news from around the biotech space including investments in Phase 2 sepsis, leukemia peptide immunotherapy, colon cancer, Phase 1 obesity, atherosclerosis, more.

    Oct 1, 2026

  • ARPA-H Launches Autism Program SPECTRA, Veeva Introduces AI Study Builder Agent, NIH Debuts PubMed Replication Tool

    Clinical Research News | Alliance trial finds fractionated radiosurgery reduces recurrence after brain metastasis surgery; FDA clears CU Anschutz CAR T-cell trial for colorectal cancer; Syneos Health and Tufts CSDD study links trial performance to operating model design; and more.

    Sep 30, 2026

  • Pancreatic Cancer Testing Model Connects to Patient Populations

    Clinical Research News | Genialis and Inventia Life Science yesterday announced a collaboration to improve how new treatments for pancreatic cancer are tested and the patients most likely to benefit are enrolled in trials. The companies will combine Genialis' AI-powered patient insights with Inventia's RASTRUM 3D cell model platform to build human-relevant models of pancreatic ductal adenocarcinoma (PDAC) that correspond to the tumor biology of identifiable patient populations.

    Sep 24, 2026

  • Condor Launches Clinical Trial Finance Agent

    Clinical Research News | Last week, Condor launched a new clinical finance agent that gives R&D teams the "why" behind variances, runs full what-if scenario planning, and then builds the resulting model directly in Condor. It's part of a team of agents built on Condor's clinical and financial ontology and knowledge graph.

    Sep 22, 2026

  • Mayo Clinic, Thermo Fisher Scientific launch Precure, LLC

    Clinical Research News | This week Mayo Clinic announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific. Precure will create one of the world’s leading biomedical datasets by integrating proteomic, genomic, and longitudinal clinical data to help researchers identify early biological signals of disease and provide a foundation for new discoveries in disease biology, diagnostics and therapeutics.

    Sep 18, 2026

  • If We Were Designing Clinical Research Today, Would We Still Separate Source Documentation from Data Capture?

    Clinical Research News | Clinical research has never been only about generating evidence that a therapy is safe or effective. It is equally about generating confidence in the evidence itself. Every observation, every assessment, every protocol deviation, every adverse event, every laboratory result, and every conclusion must be supported by documentation that can withstand scrutiny. We work in a profession built on verification. “Trust but verify” is woven into our quality systems. “If it wasn't documented, it wasn't done” is probably the most recognized sentence in our field.

    Sep 16, 2026

  • The Adherence Imperative: Clinical Operations and Patient Centricity

    Clinical Research News | Participant adherence is a leading indicator of trial health. Adherence reflects patient centricity as a measure of how effectively a clinical trial has removed barriers, supported participants throughout the study journey and enabled sites to deliver a high-quality participant experience. As participant experiences improve, usually so does adherence, especially considering that approximately half of all dropouts in phases 2-3 come down to participant choice rather than adverse reactions or study staff decisions.

    Sep 11, 2026

  • Global Effort to Overhaul Regulatory Framework for AI Medical Devices

    Clinical Research News | Data routinely captured to track health and measure wellness do not reflect ground truth, as is well known in the field of medical informatics. That imperfect healthcare data is nonetheless being used to train artificial intelligence (AI) models powering devices used in patient care, often having never been evaluated on their clinical effectiveness.

    Sep 8, 2026

  • The Scope of Things: Source Preparation Emerges as a Clinical Trial Startup Bottleneck

    Clinical Research News | Clinical trial startup delays are often attributed to budgets, contracts, and regulatory review, but a less visible bottleneck may occur at the investigative site level: source preparation. During the latest episode of The Scope of Things, Ken Getz, executive director of the Tufts Center for the Study of Drug Development, and Rick Ward, chief commercial officer at CRIO, discussed their companies’ collaboration exploring how preparing source documents delays getting the first patient in and slows enrollment.

    Sep 3, 2026

  • FDA's Real-Time Clinical Trials Initiative Takes Shape: What Near-Live Data Sharing Means for Sponsors and Operations

    Clinical Research News | The FDA's Real-Time Clinical Trials (RTCT) initiative is testing whether earlier access to selected clinical trial data can improve regulatory oversight by allowing reviewers to observe selected safety and efficacy signals while studies remain underway. Under the proof-of-concept pilot announced in April, participating sponsors share agreed-upon data elements rather than giving FDA reviewers unrestricted access to complete trial databases.

    Sep 1, 2026

  • Real-Time Clinical Trials Need a Human Exception Log

    Clinical Research News | Clinical research is getting faster. The FDA’s Operation TrialBlazer is explicitly aimed at accelerating and modernizing clinical development, while the agency has also been building toward real-time clinical trials. Faster signal flow is a meaningful advance. It can reduce the delay between what happens in a trial and what regulators or sponsors can see. But it also changes the human work around the data.

    Aug 28, 2026

  • Follow the Money: Bioanalysis Platform, Limbal Stem Cell Deficiency, Bispecific Antibody-Drug Conjugates

    Clinical Research News | Expedition Therapeutics advances its lead COPD treatment into phase 2; Ratio Therapeutics continues a clinical study of a targeted radiotherapeutic for advanced sarcomas; Abcuro prepares to launch a registration-enabling study for inclusion body myositis; and more.

    Aug 26, 2026

  • Baylor College to Open Xenoliver Transplant Center, Imperial College London, ProAxsis Collaborate, NORD Announced Three New Additions

    Clinical Research News | Owkin announced a data collaboration with Kognitic; TrialAssure’s ANONYMIZE platform has been selected by the European Medicines Agency as an official anonymization tool; The Stein Institute for Research on Aging at the University of California San Diego shall serve as the Central Laboratory and Biorepository for the XPRIZE Healthspan Competition; and more.

    Aug 25, 2026

  • MD Anderson: Immune System Provides Biological Blueprint for Treating Cancer-Related Depression with Psychedelics

    Clinical Research News | Since the brain and body are inexorably connected and seem to modulate each other, it follows that the best way to help cancer patients suffering from depression is to view the condition holistically based on their systemic and brain biology and not just their lived experience. To that end, psychedelics like ketamine and psilocybin are actively entering the treatment paradigm.

    Aug 19, 2026

  • DIOSynVax Advances Broadly Protective Vaccine Platform with Phase 1 Proof of Concept

    Clinical Research News | Digital Immune-Optimized Synthetic vaccines (DIOSynVax) is betting that the future of vaccination lies not in chasing individual viral variants, but in designing broadly protective vaccines that target entire virus families. The University of Cambridge spinout is using artificial intelligence (AI), genomics, synthetic biology, and immunology to create vaccine antigens that could be delivered through a range of existing vaccine platforms, with early clinical data supporting the concept.

    Aug 18, 2026

  • Management of Co-Occurring Conditions of Down Syndrome Becoming More Personalized

    Clinical Research News | Medical conditions vary widely in presentation, progression, and treatment response, with Down syndrome standing out as one of the most variable of all. The genetic occurrence, caused by an extra copy of chromosome 21, is widely considered one of the most heterogenous conditions, with highly variable clinical presentation from person to person.

    Aug 13, 2026